Conexeu Sciences Inc.

Conexeu Sciences Inc. announced the completion of its 12-month P.R.O.O.F. preclinical study for its CXU™ tissue-restoration platform, positioning it for the large-volume body contouring market. The company aims to create a new 'bioregeneration' category, addressing a significant unmet need in medical aesthetics, including tissue changes following GLP-1 weight loss. Conexeu plans to submit a 510(k) application for its lead candidate in Q1 2027, leveraging a market projected to reach billions by 2030.

Conexeu Sciences Inc. announced the completion of its 12-month P.R.O.O.F (Performance and Regeneration Outcomes of Flowable Collagen) preclinical study for its CXU™ platform. The study demonstrated successful tissue restoration in facial and large-volume models, and met performance benchmarks for injectable aesthetics, providing an evidence base for its planned entry into the medical aesthetics market. The company aims to address a growing tissue-restoration gap, particularly driven by the GLP-1 weight-loss drug market, and plans a Q1 2027 510(k) submission in wound care as its initial regulatory step.

Conexeu Sciences Inc. announced the opening of its new research and development facility at adMare BioInnovations' M4 Innovation Centre in Vancouver, Canada. This expansion marks a significant step in advancing the company's regenerative tissue technologies, including its proprietary CXU™ platform and B.R.E.A.S.T.™ 3D-bioprinted breast matrix. The new laboratory will serve as the hub for ongoing research, product development, and commercialization efforts, with an anticipated 510(k) submission in early 2027.

Conexeu Sciences Inc. (CNXU) filed its 10-Q report for the period ending April 30, 2026. The company reported a significant increase in net loss for both the three-month and six-month periods compared to the previous year, driven by a substantial rise in operating expenses. Despite the increased losses, cash and cash equivalents saw an increase, though the company's accumulated deficit and limited operating history raise concerns about its going concern status. The company continues to focus on developing cellular therapies for skin restoration.

Conexeu Sciences Inc. announced significant additions to its leadership team, effective immediately. Ana Bastiani-Posner, April Burke, and Andrew Costa were appointed to the Board of Directors, bringing expertise in healthcare, finance, and strategic growth. Co-Founder David Bogart was named Chief Commercial Officer to lead commercialization efforts. Additionally, Melinda Farina joined the advisory board, adding deep experience in medical aesthetics. These appointments aim to support the company's growth phase and commercialization strategy for its CXU™ platform.

Conexeu Sciences Inc. issued a total of 516,667 shares of common stock through the exercise of various warrants, generating approximately $166,767 in gross proceeds. This includes 416,667 shares issued on June 4, 2026, as part of a warrant exercise incentive program, which also resulted in the issuance of 416,667 new incentive warrants. Additionally, 100,000 shares were issued on June 8, 2026, from performance warrants. The proceeds will be used for general working capital.

Conexeu Sciences Inc. announced it will ring the Nasdaq Closing Bell on June 10, 2026, to commemorate its recent public listing and the commencement of trading under the ticker symbol CNXU. President and CEO Miles Harrison will lead the ceremony, celebrating recent milestones such as the development of B.R.E.A.S.T. and the launch of a preclinical program. The biotechnology company focuses on advancing tissue regeneration through its proprietary CXU platform, targeting significant markets like wound care and body contouring.

Conexeu Sciences Inc. announced the launch of a preclinical development program for its B.R.E.A.S.T.™ (BIO-REGENERATIVE ERGONOMICALLY ARCHITECTED SMART TISSUE™) 3D-printed bioregenerative breast matrix. The program, conducted at the Wake Forest Institute for Regenerative Medicine (WFIRM), will evaluate the durability, host tissue integration, and resorbability of the proprietary CXU™ 3D-printed matrix. This initiative is a significant step in advancing the company's regenerative medicine strategy and aims to develop an alternative to traditional breast implants and reconstruction approaches. Conexeu anticipates a 510(k) submission for its initial indication in early 2027.

Conexeu Sciences Inc. issued 4,342,648 shares of common stock on May 12, 2026, from the exercise of warrants, generating approximately $1,963,967 for general working capital. This action was part of a warrant exercise incentive program, which also led to the issuance of 4,342,648 additional transferable common stock purchase warrants. The company also issued 11,175 compensatory shares to a director on May 14, 2026.